JP2022550670A5 - - Google Patents

Info

Publication number
JP2022550670A5
JP2022550670A5 JP2022512828A JP2022512828A JP2022550670A5 JP 2022550670 A5 JP2022550670 A5 JP 2022550670A5 JP 2022512828 A JP2022512828 A JP 2022512828A JP 2022512828 A JP2022512828 A JP 2022512828A JP 2022550670 A5 JP2022550670 A5 JP 2022550670A5
Authority
JP
Japan
Prior art keywords
sequence
transcripts
nlrc4
human
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022512828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550670A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047640 external-priority patent/WO2021041317A1/en
Publication of JP2022550670A publication Critical patent/JP2022550670A/ja
Publication of JP2022550670A5 publication Critical patent/JP2022550670A5/ja
Withdrawn legal-status Critical Current

Links

JP2022512828A 2019-08-23 2020-08-24 炎症性疾患のためのｄｄｘ１７及びｎｌｒｃ４標的化 Withdrawn JP2022550670A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962891124P 2019-08-23 2019-08-23
US62/891,124 2019-08-23
PCT/US2020/047640 WO2021041317A1 (en) 2019-08-23 2020-08-24 Ddx17 and nlrc4 targeting for inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2022550670A JP2022550670A (ja) 2022-12-05
JP2022550670A5 true JP2022550670A5 (enExample) 2023-09-06

Family

ID=74685756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022512828A Withdrawn JP2022550670A (ja) 2019-08-23 2020-08-24 炎症性疾患のためのｄｄｘ１７及びｎｌｒｃ４標的化

Country Status (8)

Country Link
US (1) US20220280543A1 (enExample)
EP (1) EP4017503A4 (enExample)
JP (1) JP2022550670A (enExample)
KR (1) KR20220066071A (enExample)
CN (1) CN114599373A (enExample)
AU (1) AU2020340298A1 (enExample)
CA (1) CA3149147A1 (enExample)
WO (1) WO2021041317A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021008751A (es) 2019-01-25 2021-11-12 Univ Brown Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
CN112608923B (zh) * 2021-01-17 2023-05-12 上海捷瑞生物工程有限公司 一种抑制ddx17相关rna表达产物的核苷酸及其应用
CN114796452B (zh) * 2021-01-28 2025-06-10 华东师范大学 炎症性皮肤疾病生物标志物DDX5和/或sIL-36R及其应用
KR102673132B1 (ko) * 2021-04-20 2024-06-12 아주대학교산학협력단 염증성 질환 치료를 위한 nlrp3 인플라마좀 억제 펩타이드
US20240139229A1 (en) * 2021-06-23 2024-05-02 University Of Kentucky Research Foundation Treatment for aortopathy
CN114106140A (zh) * 2021-11-23 2022-03-01 哈尔滨医科大学附属肿瘤医院 一种表达特定sting异构体、细胞系、制备方法、用途
CA3244283A1 (en) * 2022-02-22 2023-08-31 Rome Therapeutics, Inc. METHODS OF TREATING MEDICAL PROBLEMS USING CENSAVUDINE OR A COMBINATION COMPOUND
KR102862426B1 (ko) * 2022-06-28 2025-09-23 가톨릭대학교 산학협력단 테노포비르 알라페나미드를 포함하는 비알콜성 지방간염 예방, 개선 또는 치료용 조성물
EP4680243A1 (en) * 2023-03-17 2026-01-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods for treatment of age-related macular degeneration
WO2025042804A1 (en) * 2023-08-18 2025-02-27 University Of Houston System Recombinant production of cyclic dinucleotides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
ES2907620T3 (es) * 2011-07-18 2022-04-25 Univ Kentucky Res Found Protección de células de la degeneración inducida por ARN Alu e inhibidores para proteger células
ES2875535T3 (es) * 2012-03-29 2021-11-10 Biogen Ma Inc Biomarcadores para su uso en aplicaciones de terapia de integrina
US9326983B2 (en) * 2013-08-01 2016-05-03 University Of Kentucky Research Foundation Compositions and methods for treating retinal degradation
DK3261644T3 (da) * 2015-02-26 2021-06-28 Univ Kentucky Res Found Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
CN105012305A (zh) * 2015-07-24 2015-11-04 福建广生堂药业股份有限公司 拉米夫定及其药用盐治疗老年性黄斑部病变的用途
GB201616557D0 (en) * 2016-09-29 2016-11-16 Secretary Of State For Health The Assay for distinguishing between sepsis and systemic inflammatory response syndrome
WO2018162271A1 (en) * 2017-03-05 2018-09-13 Rita Dobmeyer Nanoparticles for the treatment of macular degeneration

Similar Documents

Publication Publication Date Title
Borea et al. Pharmacology of adenosine receptors: the state of the art
JP6875454B2 (ja) Ｈｉｖを治療するためのトール様受容体の調節因子
JP2026004417A (ja) ＳＡＲＳ ＣｏＶ－２感染を治療するための方法
US9617547B2 (en) Chiral nucleic acid adjuvant
TW202104210A (zh) Hiv蛋白酶抑制劑
AU2021200857B2 (en) Crystalline forms of tenofovir alafenamide
US11939581B2 (en) Methods and compositions for targeting PD-L1
CN119139338A (zh) 抗covid-19的高活性化合物
CN110430894A (zh) 编码活化致癌基因突变肽的免疫调节治疗性mrna组合物
US20110009477A1 (en) Oligonucleotide-based compounds as inhibitors of toll-like receptors
JP2003510282A (ja) 免疫刺激核酸
JP2010536787A (ja) Ｔｏｌｌ様受容体モジュレータ
AU2016225037B2 (en) Compositions and methods for treating retinal degradation
JP2015518711A (ja) Ｂｄｎｆ発現を調節するための組成物及び方法
CN117580587B (zh) 基于源自SARS-CoV-2奥密克戎毒株的序列的冠状病毒核酸疫苗
JP2010526883A (ja) 皮膚潰瘍の治療方法
TW202221122A (zh) Ｂ型肝炎患者之寡核苷酸治療
WO2023102472A1 (en) Antiviral prodrugs and formulations thereof
ES2392449T3 (es) Modulación antisentido de la expresión de la integrina alfa-4
TW202342753A (zh) 狂犬病核酸疫苗
TW202126304A (zh) 使用核心蛋白異位調節劑治療hbv感染之方法
CN113440533B (zh) 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用
CN111971049A (zh) 促进免疫应答
JP2025141815A (ja) アンチセンスオリゴヌクレオチドの甲状腺異常による疾患を治療する薬剤の調製における使用
EP4527934A1 (en) Gene delivery system based on metal nanoparticle-nucleic acid conjugate